Transarterial Chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: A meta-analysis

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Zhang, Leida ^a   Hu, Peng ^a   Chen, Xi ^a   Bie, Ping ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SORAFENIB; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ABDOMINAL PAIN; ADVERSE DRUG REACTION; ARTICLE; CANCER GROWTH; CANCER STAGING; CHEMOEMBOLIZATION; CONFIDENCE INTERVAL; DESQUAMATION; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; EMBASE; FATIGUE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HAZARD RATIO; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; INFORMATION RETRIEVAL; LIVER CELL CARCINOMA; MEDLINE; META ANALYSIS; NAUSEA; OBJECTIVE RESPONSE RATE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PUBLICATION; STATISTICAL MODEL; SYSTEMATIC REVIEW; TIME TO PROGRESSION; VOMITING; AGED; ANALOGS AND DERIVATIVES; ARTERY; CANCER GRADING; CARCINOMA, HEPATOCELLULAR; COMPARATIVE STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TIME;

AGED; ARTERIES; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; TIME FACTORS;

EID: 84903309872     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100305     Document Type: Article

References (34)

1. Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379: 1245-1255.
2. Yuen MF, Hou JL, Chutaputti A (2009) Hepatocellular carcinoma in the Asia-Pacific region. J Gastroenterol Hepatol 24: 346-53.
3. Asia-Pacific working party on prevention of hepatocellular carcinoma (2010) Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements. J Gastroenterol Hepatol 25: 657-63.
4. Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, et al. (2000) Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. Hepatology 32: 1224-1229.
5. Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37: 429-442.
6. Ikai I, Arii S, Kojiro M, Ichida T, Makuuchi M, et al.(2004) Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 101: 796-802.
7. Bruix J, Sala M, Llovet JM (2004) Chemoembolization for hepatocellular carcinoma. Gastroenterology 127: S179-S188.
8. Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-1022.
9. Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, et al. (2008) Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 103: 914-921.
10. Chang YS, Adnane J, Trail PA, Levy J, Henderson A, et al. (2007) Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 59: 561-74.
11. Cabrera R, Pannu DS, Caridi J, Firpi RJ, Soldevila-Pico C, et al. (2011) The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Aliment Pharmacol Ther 34: 205-213.
12. Wells G, Shea B, O'connell D, Peterson J, Welch V, et al. (2000) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. 3rd Symposium on Systematic Reviews: Beyond the Basics: 3-5.
13. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16.
14. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748.
15. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
16. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
17. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
18. Egger M, Davey Smith G, Schneider M, Minder C(1997) Bias in meta-analysis detected by a simple, graphical test. Br Med J 315: 629-634.
19. Bai W, Wang YJ, Zhao Y, Qi XS, Yin ZX, et al. (2013) Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: A propensity score matching study. Journal of Digestive Diseases 14: 181-190.
20. Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, et al.(2011) Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. European Journal Of Cancer 47: 2117-2127.
21. Sansonno D, Lauletta G, Russi S, Conteduca V, Sansonno L, et al. (2012) Transarterial Chemoembolization Plus Sorafenib: A Sequential Therapeutic Scheme for HCV-Related Intermediate-Stage Hepatocellular Carcinoma: A Randomized Clinical Trial. The Oncologist 17: 359-366.
22. Muhammad A, Dhamija M, Vidyarthi G, Amodeo D, Boyd W, et al. (2013) Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma. World J Hepatol 5: 364-371.
23. Choi GH, Shim JH, Kim MJ, Ryu MH, Ryoo BY, et al. (2013) Sorafenib Alone versus Sorafenib Combined with Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: Results of Propensity Score Analyses. Radiology 269: 603-611.
24. Qu XD, Chen CS, Wang JH, Yan ZP, Chen JM, et al. (2012) The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma. BMC Cancer 12: 263.
25. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
26. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109.
27. Mathonnet M, Descottes B, Valleix D, Labrousse F, Truffinet V, et al.(2006) Quantitative analysis using ELISA of vascular endothelial growth factor and basic fibroblast growth factor in human colorectal cancer, liver metastasis of colorectal cancer and hepatocellular carcinoma. World J Gastroenterol 12: 3782-3.
28. Zhang T, Ding X, Wei D, Cheng P, Su X, et al (2010) Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials. Anti-Cancer Drugs 21: 326-332.
29. Zhang T, Ding X, Wei D, Cheng P, Su X, et al. (2012) Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review. Hepatobiliary Pancreat Dis Int 11: 458-466.
30. Kunz R, Oxman AD (1998) The unpredictability paradox: Review of empirical comparisons of randomized and non-randomized clinical trials. BMJ 317: 1185-1190.
31. Bayer (2013) A phase II randomized, double-blind, placebo-controlled study of sorafenib or placebo in combination with transarterial chemoembolization (TACE) performed with DC bead and doxorubicin for intermediate stage hepatocellular carcinoma (HCC). Available at: http://clinicaltrials.gov/ ct2/show/NCT00855218?term=sorafenib+TACE&rank=10.
32. Chao Y, Yoon J, Li C (2010) START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial. 2010 ASCO Gastrointestinal Cancers Symposium, Orlando, FL, USA.
33. Lencioni R, Zou J, Leberre M (2010) Sorafenib (SOR) or placebo (PL) in combination with transarterial chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma (SPACE). J Clin Oncol 28: [Abstract TPS178].
34. Park J-W, Kim HY, Shim JH (2010) Interim analysis of a phase II study of the combination of TACE and sorafenib for unresectable hepatocellular carcinoma in National Cancer Center Korea (COTSUN Korea Trial). In: Proceedings of the fourth annual conference of the International Liver Cancer Association (ILCA), Montreal, Quebe c, Canada; 10-12 September 2010. p. 26 [Abstract O-027].